Treatment of Pharyngeal Chlamydia
Doxycycline 100 mg twice daily for 7 days is the preferred treatment for pharyngeal chlamydia due to higher eradication rates compared to azithromycin. 1
First-Line Treatment Options
Doxycycline: 100 mg orally twice daily for 7 days
Azithromycin: 1 g orally in a single dose
Special Populations
Pregnant Patients
- Erythromycin base: 500 mg orally four times daily for 7 days 3
- Erythromycin ethylsuccinate: 800 mg orally four times daily for 7 days 3
- Amoxicillin: 500 mg orally three times daily for 7-10 days (if erythromycin not tolerated) 4
Children and Adolescents
- For children who weigh <45 kg: Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days 4
- For children who weigh >45 kg but are aged <8 years: Azithromycin 1 g orally in a single dose 4
- For children aged >8 years: Azithromycin 1 g orally in a single dose OR Doxycycline 100 mg orally twice daily for 7 days 4
Follow-Up Recommendations
Test of cure: Not routinely recommended after treatment with doxycycline or azithromycin unless symptoms persist 3
Rescreening: Consider rescreening 3-4 months after treatment due to high risk of reinfection 3
Partner Management
- All sexual partners from the previous 60 days should be evaluated, tested, and treated 3
- Patients should abstain from sexual intercourse for 7 days after single-dose therapy or until completion of multi-day regimen 3
- Sexual abstinence should continue until all partners have been treated 3
Important Clinical Considerations
- Medication administration: Ideally dispense on-site with first dose directly observed to maximize compliance 3
- Concurrent STI testing: Always test for other STIs, especially gonorrhea which commonly co-occurs with chlamydial infections 3
- Contraindications:
Treatment Efficacy Comparison
Research specifically comparing treatments for pharyngeal chlamydia shows doxycycline (98% effective) outperforms azithromycin (90% effective) 1. This differs from genital chlamydia where both treatments show similar efficacy. The anatomical differences between pharyngeal and genital sites likely affect drug penetration and efficacy.